17,261 trials
Diffuse Large B-Cell Lymphoma
Primary: Complete Response (CR) Rate — 64.5; 63.5 percentage of participants — p=0.915
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cancer
Primary: Best Overall Response — 0; 0; 13; 11 participants
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Richter's Transformation · Leukemia
Primary: Maximum Total Tolerated Dose (MTD) of Daily Combination Fludarabine 30 mg/m^2 and Cytarabine 500 mg/m^2 Among 3 Dose Levels (Dose Level 1: 2 Days, Dose Level 2: 3 Days…
Oligospermia
Primary: Changes From Baseline in the Seminal Fluid Characteristics Throughout the Study — 3.47; 3.20 ml
HIV-1 Infection
Primary: Change in Endotoxin — 0.20 pg/mL — p=0.87
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 8 participants
Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer · Stage IIA Pancreatic Cancer
Primary: Proportion of Patients With Specific Protocol Defined Adverse Event at Conclusion of All Therapy — 0.30; 0.25 Proportion of patients
Malaria
Primary: Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human…
Lung Cancer
Primary: Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical…
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Six Month Survival Rate — 25; 67; 33 percentage of patients
Esophageal Cancer
Primary: Complete Response — 27.78 percentage of patients
Alcohol Dependence · Alcohol Abuse
Primary: Percent Heavy Drinking Days — 0.63; 0.14; 0.09; 0.17 percentage of days
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 34.6 percentage of participants
Postherpetic Neuralgia
Primary: Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF) — -0.94; -0.97 units on a scale